RYTM · Rhythm Pharmaceuticals, Inc.
$89.27
-1.79% last session
End-of-day data · close of 2026-10-23
Market cap
$6B
Enterprise value
$6B
Trailing P/E
—
Forward P/E
-142.0
Dividend yield
0.0%
Beta
2.01
Avg volume
1M
Employees
0K
Daily Change %
-1.79%
5 Days Change
5.49%
10 Days Change
4.95%
30 Days Change
-7.47%
60 Days Change
-18.43%
Month to Day Change
-2.69%
Year to Day Change
-15.08%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RYTM
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-16
Latest call per bank · past 12 months
JP Morgan
Overweight$145
+62.4% vs priceRBC Capital
Outperform$159
+78.1% vs priceDeutsche Bank
Hold$120
+34.4% vs priceCitigroup
Buy$143
+60.2% vs priceWells Fargo
Overweight$155
+73.6% vs priceBank of America
Buy$149
+66.9% vs priceMorgan Stanley
Overweight$136
+52.3% vs priceGoldman Sachs
Buy$157
+75.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | William Blair | Initiates | Outperform | $0.00 |
| 2026-10-15 | JP Morgan | Maintains | Overweight | $146 → $145 |
| 2026-10-12 | HC Wainwright & Co. | Maintains | Buy | $105 → $130 |
| 2026-10-08 | RBC Capital | Maintains | Outperform | $155 → $159 |
| 2026-08-28 | Deutsche Bank | Initiates | Hold | $0.00 → $120 |
| 2026-08-07 | JP Morgan | Maintains | Overweight | $145 → $146 |
| 2026-08-05 | Citigroup | Maintains | Buy | $142 → $143 |
| 2026-08-05 | RBC Capital | Maintains | Outperform | $141 → $155 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 10.2% below the 50-day MA ($99.41).
- bearish: Price vs 200-day MA: Trading 8.4% below the 200-day MA ($97.42).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.59) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($75.82) and high ($117.62).
RYTM Price Chart
Loading chart for RYTM…
Fundamentals
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.